Pharmacological treatment based on inhibition of the NRF2– kelch-like ECH associated protein 1 (KEAP1) signaling pathway has successfully been applied in treatment of diabetic kidney disease [16]. This evidence concerns the gene KEAP1 and diabetic kidney disease.